vs
Side-by-side financial comparison of Dolby Laboratories, Inc. (DLB) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $346.7M, roughly 1.4× Dolby Laboratories, Inc.). Dolby Laboratories, Inc. runs the higher net margin — 15.4% vs 6.8%, a 8.6% gap on every dollar of revenue. On growth, Pediatrix Medical Group, Inc. posted the faster year-over-year revenue change (-1.7% vs -2.9%). Over the past eight quarters, Dolby Laboratories, Inc.'s revenue compounded faster (9.6% CAGR vs -0.1%).
Dolby Laboratories, Inc. is an American technology corporation specializing in audio noise reduction, audio encoding/compression, spatial audio, and high-dynamic-range television (HDR) imaging. Dolby licenses its technologies to consumer electronics manufacturers.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
DLB vs MD — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $346.7M | $493.8M |
| Net Profit | $53.3M | $33.7M |
| Gross Margin | 87.5% | — |
| Operating Margin | 17.9% | 9.9% |
| Net Margin | 15.4% | 6.8% |
| Revenue YoY | -2.9% | -1.7% |
| Net Profit YoY | -21.4% | 10.5% |
| EPS (diluted) | $0.55 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $346.7M | — | ||
| Q4 25 | $346.7M | $493.8M | ||
| Q3 25 | $307.0M | $492.9M | ||
| Q2 25 | $315.5M | $468.8M | ||
| Q1 25 | $369.6M | $458.4M | ||
| Q4 24 | $357.0M | $502.4M | ||
| Q3 24 | $304.8M | $511.2M | ||
| Q2 24 | $288.8M | $504.3M |
| Q1 26 | $53.3M | — | ||
| Q4 25 | $53.3M | $33.7M | ||
| Q3 25 | $49.3M | $71.7M | ||
| Q2 25 | $46.1M | $39.3M | ||
| Q1 25 | $91.8M | $20.7M | ||
| Q4 24 | $67.8M | $30.5M | ||
| Q3 24 | $58.6M | $19.4M | ||
| Q2 24 | $38.4M | $-153.0M |
| Q1 26 | 87.5% | — | ||
| Q4 25 | 87.5% | — | ||
| Q3 25 | 87.1% | — | ||
| Q2 25 | 86.1% | — | ||
| Q1 25 | 90.3% | — | ||
| Q4 24 | 88.6% | — | ||
| Q3 24 | 88.8% | — | ||
| Q2 24 | 87.7% | — |
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.9% | 9.9% | ||
| Q3 25 | 9.7% | 13.8% | ||
| Q2 25 | 15.1% | 12.8% | ||
| Q1 25 | 29.2% | 7.0% | ||
| Q4 24 | 22.4% | 7.8% | ||
| Q3 24 | 15.2% | 6.6% | ||
| Q2 24 | 12.7% | -31.3% |
| Q1 26 | 15.4% | — | ||
| Q4 25 | 15.4% | 6.8% | ||
| Q3 25 | 16.1% | 14.5% | ||
| Q2 25 | 14.6% | 8.4% | ||
| Q1 25 | 24.8% | 4.5% | ||
| Q4 24 | 19.0% | 6.1% | ||
| Q3 24 | 19.2% | 3.8% | ||
| Q2 24 | 13.3% | -30.3% |
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.55 | $0.40 | ||
| Q3 25 | $0.50 | $0.84 | ||
| Q2 25 | $0.48 | $0.46 | ||
| Q1 25 | $0.94 | $0.24 | ||
| Q4 24 | $0.70 | $0.37 | ||
| Q3 24 | $0.59 | $0.23 | ||
| Q2 24 | $0.40 | $-1.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $644.6M | $375.2M |
| Total DebtLower is stronger | — | $570.5M |
| Stockholders' EquityBook value | $2.6B | $865.9M |
| Total Assets | $3.2B | $2.2B |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $644.6M | — | ||
| Q4 25 | $644.6M | $375.2M | ||
| Q3 25 | $702.6M | $340.1M | ||
| Q2 25 | $699.3M | $224.7M | ||
| Q1 25 | $626.6M | $99.0M | ||
| Q4 24 | $520.8M | $229.9M | ||
| Q3 24 | $482.0M | $103.8M | ||
| Q2 24 | $869.0M | $19.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $570.5M | ||
| Q3 25 | — | $577.2M | ||
| Q2 25 | — | $583.9M | ||
| Q1 25 | — | $590.5M | ||
| Q4 24 | — | $597.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | $865.9M | ||
| Q3 25 | $2.6B | $890.7M | ||
| Q2 25 | $2.6B | $833.8M | ||
| Q1 25 | $2.6B | $789.2M | ||
| Q4 24 | $2.5B | $764.9M | ||
| Q3 24 | $2.5B | $732.5M | ||
| Q2 24 | $2.4B | $706.5M |
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $2.2B | ||
| Q3 25 | $3.2B | $2.2B | ||
| Q2 25 | $3.2B | $2.1B | ||
| Q1 25 | $3.2B | $2.0B | ||
| Q4 24 | $3.2B | $2.2B | ||
| Q3 24 | $3.1B | $2.1B | ||
| Q2 24 | $3.0B | $2.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $54.8M | $114.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.03× | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $54.8M | — | ||
| Q4 25 | $54.8M | $114.1M | ||
| Q3 25 | $472.2M | $137.3M | ||
| Q2 25 | $67.7M | $137.2M | ||
| Q1 25 | $174.9M | $-117.5M | ||
| Q4 24 | $106.8M | $133.0M | ||
| Q3 24 | $327.3M | $91.8M | ||
| Q2 24 | $21.3M | $107.0M |
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | — | ||
| Q3 25 | $435.9M | — | ||
| Q2 25 | $61.3M | — | ||
| Q1 25 | $168.0M | — | ||
| Q4 24 | $100.0M | — | ||
| Q3 24 | $297.2M | — | ||
| Q2 24 | $13.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | — | ||
| Q3 25 | 142.0% | — | ||
| Q2 25 | 19.4% | — | ||
| Q1 25 | 45.5% | — | ||
| Q4 24 | 28.0% | — | ||
| Q3 24 | 97.5% | — | ||
| Q2 24 | 4.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | — | ||
| Q3 25 | 11.8% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | 2.6% | — |
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.03× | 3.39× | ||
| Q3 25 | 9.57× | 1.91× | ||
| Q2 25 | 1.47× | 3.49× | ||
| Q1 25 | 1.91× | -5.66× | ||
| Q4 24 | 1.57× | 4.36× | ||
| Q3 24 | 5.59× | 4.72× | ||
| Q2 24 | 0.55× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DLB
| Licensing | $319.8M | 92% |
| Products and services | $26.9M | 8% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
